More than 40,000 cancer doctors, researchers, and trial scientists converged on Chicago for the world’s largest cancer conference, and what they brought with them was striking: a daily pill that doubled survival time for one of medicine’s most resistant tumors, a vaccine built from a person’s own cancer cells that just passed its biggest test ever, and evidence that tens of thousands of women a year can safely skip chemotherapy altogether. Cancer research has spent decades chipping away at targets once considered impossible to reach. In 2026, several of those walls came down at once.
The pill that unlocked a 40-year-old dead end
For nearly four decades, researchers knew exactly what was driving one of the deadliest cancers: a single faulty part buried inside more than 9 in 10 of these tumors, sending a constant signal to keep growing. The body cannot shut it down on its own. Doctors knew the fault was there, but every attempt to build a drug against it failed for one basic reason: most drugs work like a key, and this target had no keyhole. Scientists had a word for it. Undruggable.
This year, a daily pill changed that framing permanently. Rather than trying to fit a key into an absent lock, the drug works more like glue. It sticks to the faulty part directly and blocks the growth signal from getting out. In a phase 3 trial of 500 patients whose cancer had spread and who had run out of other options, half continued on standard chemotherapy and half switched to the pill. The people on chemo lived under seven months on average. The people on the pill lived around 13. Roughly double, and with fewer harsh side effects. The researchers were careful to say what this is not: it is not a cure. But it is the first treatment to clearly beat chemotherapy for this cancer, and at the Chicago conference, the announcement drew a standing ovation.
A separate result came from a rare cancer that grows in the body’s soft tissue, one for which chemotherapy barely worked and doctors had little else to offer. Inside these tumors, two genes are copied too many times. Researchers focused on the first and found a drug already being used against breast cancer that could target it. They ran a phase 3 trial comparing the drug against a dummy pill, because nothing else worked well enough to test against. On the dummy pill, the cancer typically worsened in about six weeks. With the drug, it held still for over nine months. Only about 1 in 10 saw their tumors shrink, but holding the cancer still, giving people months of stability where none existed before, was itself a first for this disease.
Earlier, smarter, and in some cases less
Not every advance this year required a new molecule. One came from asking what would happen if a drug that already worked was given sooner. When lung cancer is caught early and removed surgically, the scans can come back clear and still not tell the whole story. Up to two thirds of patients see the cancer return, because cells too small for any scan to detect have already spread and are simply waiting. Researchers knew of a genetic fault present in roughly 1 to 2 in every 100 lung cancers, and a drug already existed for it. The question was whether giving it right after surgery, before those hidden cells could multiply, would change the outcome.
In a phase 3 trial across 22 countries, it did. On a dummy pill, 70% showed no sign of the cancer returning after two years. With the drug, that figure rose to 94%. All three deaths during the trial period occurred in the group without the drug.
Breast cancer research this year pointed in a different direction entirely: doing less, on purpose. For hormone-driven breast cancers, doctors have long faced a judgment call after surgery, add chemotherapy or hold off. When uncertain, they gave it just in case. But a genomic test that reads how the tumor is actually behaving, not just its size, can now predict whether chemo will help or make no difference at all. In a phase 3 trial of over 4,000 high-risk women, those who took the test first saw more than two thirds of their group cleared to skip chemotherapy entirely and take a gentler hormone treatment instead. Five years later, they were doing just as well as the women who went through chemo. In the UK alone, the researchers estimate this could spare around 5,000 women a year from chemotherapy they do not need.
Prostate cancer saw a different kind of improvement. For the highest-risk cases, where the cancer returns in up to half of men within five years even after surgery, a trial of just over 2,000 men tested giving an existing prostate cancer drug at two moments: before surgery to weaken the tumor, and again after to clear what remained. Men on standard treatment typically went three and a half years before the cancer required attention again. With the drug at both stages, that stretched to over six years, and they were roughly 20% less likely to see it spread.
The vaccine that cleared its final test
One of the oldest ideas in oncology is to train the immune system to recognize cancer the way it recognizes an infection. Every tumor carries tiny markers that healthy cells do not have. A personalized vaccine built from a sample of a patient’s own tumor can point the immune system directly at those markers and instruct it to hunt down any cells left behind after surgery.
More than 120 trials of these vaccines are currently running. In melanoma, an earlier small trial had already cut the risk of the cancer spreading by more than half. But no cancer vaccine had ever cleared a large final-stage trial. Then, just as this reporting was being completed, that same melanoma vaccine did exactly that, in a trial of over 1,000 people. It worked again. Fewer people saw their cancer return. No cancer vaccine has ever reached this point before.
Elsewhere, a new immune-cell therapy reprogrammed to fight a solid tumor was approved in China, described as a world first for that class of cancer. Researchers are testing tiny radioactive particles designed to find tumors and destroy them from the inside while leaving surrounding healthy tissue largely untouched. And a separate vaccine is being trialed not to treat lung cancer but to prevent it from developing at all.
A sample that traveled to Chicago
Among the 83 patients enrolled in one phase 1 trial, all of them had stopped responding to every available treatment across six different cancer types. A new drug designed to make tumors visible to the immune system again produced some level of shrinkage in almost one in three of them.
At the Chicago conference this year, doctors and researchers shared results from a single phase 3 trial in bladder cancer. Adding one drug to the standard chemotherapy-and-radiation approach left more than 8 in 10 patients cancer-free a year later, with their bladder intact. Earlier trials using chemo and radiation alone had left closer to 6 in 10 in that position.
The largest phase 3 trial ever run for high-risk prostate cancer of this kind enrolled just over 2,000 men. The results from the lung cancer drug trial are still ongoing, with the full follow-up not yet complete. Most of the trials described here have not yet reached regulatory approval or been written into treatment guidelines, and the researchers themselves are measured about what comes next. But the direction is visible. One of the doctors presenting at the conference put the pill result plainly: ‘This isn’t a cure, but it’s the first time anything has clearly beaten chemo for this cancer.’
The 157-person melanoma vaccine trial that first showed a result years ago sat largely unremarked outside specialist circles. The 1,000-person trial that just confirmed it is a different matter.
